By 2030, it is anticipated that the UK Lung Cancer Therapeutics Market will reach a value of $1245 Mn from $775 Mn in 2022, growing at a CAGR of 6.1% during 2022-30. The Lung Cancer Therapeutics Market in the UK is dominated by a few domestic pharmaceutical companies such as Scancell, Sareum Holdings, and AstraZeneca. The Lung Cancer Therapeutics Market in the UK is segmented into different types of cancer and different therapy types. Some of the major factors affecting the UK lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.
By 2030, it is anticipated that the UK Lung Cancer Therapeutics market will reach a value of $1245 Mn from $775 Mn in 2022, growing at a CAGR of 6.1% during 2022-30.
The UK is a high-income, developed island country spanning an archipelago including Great Britain, located in Western Europe comprising England, Scotland, Wales, and Northern Ireland. After breast and prostate cancer, lung cancer is the third most frequent cancer in the UK, accounting for 13% of all new cancer cases. Every year, around 43,000 people in the UK are diagnosed with the illness.
According to the latest WHO data published in 2020 Lung Cancers Deaths in the United Kingdom reached 35,715 or 6.98% of total deaths. The age-adjusted Death Rate is 24.68 per 100,000 population ranks the United Kingdom 29th in the world. UK's government spends 12 % of its GDP on healthcare.
Market Growth Drivers
As part of their main cancer treatment, 2% of patients with small cell lung cancer (SCLC) and 16% of patients with Non-small cell lung cancer (NSCLC) have surgery to remove the tumour. Radiotherapy is used as part of the primary cancer treatment for 42 % of patients with small cell lung cancer (SCLC) and 27 % of patients with non-small cell lung cancer (NSCLC). As part of their main cancer treatment, 68 % of patients with small cell lung cancer (SCLC) and 25 % of patients with non-small cell lung cancer (NSCLC) received chemotherapy. In lung cancer treatment, there has also been a tendency toward personalised medicine, in which treatment is tailored to the individual genetic profile of each patient's cancer.
Many patients have benefited from this method. In addition to these breakthroughs in treatment, there is a focus on improving lung cancer detection and diagnosis. Screening programmes for high-risk persons have been developed in several parts of the UK, potentially leading to earlier disease discovery and treatment. These aspects could boost the UK Lung Cancer Therapeutics market.
Market Restraints
Age and health state can both influence the type of lung cancer therapy that is most suited. Certain therapies, such as chemotherapy or radiation therapy, may not be tolerated by older individuals or those with underlying health issues. It is uncommon in people under the age of 40. More than four out of every ten persons diagnosed with lung cancer in the UK are 75 or older. It is vital to observe regulatory guidelines established by organisations such as the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) while producing new medications and therapies. These criteria can be complicated and time-consuming, resulting in delays and higher expenses. These factors may deter new entrants into the UK Lung Cancer Therapeutics market.
Key Players
March 2023: Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, has announced a Research Agreement with Bicycle Therapeutics, a biotechnology company pioneering a new and distinct class of therapeutics based on its proprietary bicyclic peptide technology. The Companies will research the possibilities of integrating technologies and methods to develop antigen-targeted diagnostic probes that use bicyclic peptides as their targeting mechanism and are coupled to Owlstone's Exogenous Volatile Organic Compound probes under the terms of the Agreement. The work will initially focus on lung cancer screening as a proof of principle for the larger opportunity by encouraging the selective accumulation of the probe at the tumour for higher signal and enhanced selectivity.
January 2022: Lung cancer patients will benefit from a ground-breaking new medicine on the NHS. Thanks to a contract negotiated by NHS England, thousands of lung cancer patients in England will have access to a ground-breaking new medicine that can greatly lower the chance of cancer recurring. The MHRA has officially authorised atezolizumab, an effective therapy for non-small cell lung cancer (NSCLC), with more than 850 patients in England projected to be eligible for the drug in the first year, increasing to more than 1000 in the third year.
Lung cancer therapeutics are regulated and reimbursed in the UK by several entities, including the Medicines and Healthcare Products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE), and the National Health Service (NHS). The MHRA is responsible for regulating medicines and medical devices in the UK. NICE evaluates the cost-effectiveness of lung cancer therapeutics and makes recommendations on whether they should be funded by the NHS. The local integrated care board (ICB) is involved to decide whether to support the doctor’s decision and pay for the medicine from NHS budgets.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type (Revenue, USD Billion):
By Therapy (Revenue, USD Billion):
By Type of Molecule (Revenue, USD Billion):
By Drug Class (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?